November 8, 2012
After a panicked Questcor (Nasdaq: QCOR ) sell-off on Friday, the stock has stabilized. What was the cause for alarm? It turns out that Questcor's champion drug, Acthar -- which has an orphan designation from the Food and Drug Administration for the treatment of infantile spasms and is the major money-maker for Questcor -- may have a major new generic competitor from abroad poised to challenge its position. And the competition is a lot cheaper. Motley Fool health care bureau chief Brenton Flynn takes us through what this may mean for the company, why the alarm over this may all be just a storm in a teacup, and what to keep your eye on going forward.
Questcor is one of the most debated names in all of biotech. Its key drug Acthar is growing at a torrid pace -- and minting money in the process. However, these recent events have created significant doubts about Questcor's future. Can this drug stay ahead of the competition and continue to be a win for investors? Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.